# Nuclide record idea-net-antagonist-ligands (idea). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/ideas/idea-net-antagonist-ligands/>
  a schema:CreativeWork ;
  nuclide:kind "idea" ;
  schema:identifier "idea-net-antagonist-ligands" ;
  schema:name "SSTR antagonist radioligands to increase tumour dose"@en ;
  schema:description "Radioligand therapy for neuroendocrine tumours built on somatostatin receptor antagonists rather than the agonists used today: antagonists bind the receptor in every state and are not internalised, so they occupy several times more sites per cell and deliver more radiation per dose. The test is a randomised phase 2 against agonist lutetium therapy."@en ;
  schema:url <https://nuclide.cc/ideas/idea-net-antagonist-ligands/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-19-1026> ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/prrt/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> .